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Abstract
Ross River virus (RRV), chikungunya virus (CHIKV), and related alphaviruses cause debilitating 
polyarthralgia and myalgia. Mouse models of RRV and CHIKV have demonstrated a role for the 
adaptive immune response in the control of these infections. However, questions remain regarding 
the role for T cells in viral control, including the magnitude, location, and dynamics of CD8+ T 
cell responses. To address these questions, we generated a recombinant RRV expressing the H-2b-
restricted gp33 determinant derived from the glycoprotein (gp) of lymphocytic choriomeningitis 
virus (LCMV) (“RRV-LCMV”). Utilizing tetramers, we tracked gp33-specific CD8+ T cells 
during RRV-LCMV infection. We found that acute RRV infection induces activation of CD8+ T 
cell responses in lymphoid and musculoskeletal tissues that peak from 10 to 14 days post-
inoculation (dpi), suggesting that CD8+ T cells contribute to control of acute RRV infection. Mice 
genetically deficient for CD8+ T cells or wild-type mice depleted of CD8+ T cells had elevated 
RRV loads in skeletal muscle tissue, but not joint-associated tissues, at 14 dpi, suggesting that the 
ability of CD8+ T cells to control RRV infection is tissue-dependent. Finally, adoptively 
transferred T cells were capable of reducing RRV loads in skeletal muscle tissue of Rag1−/− mice, 
indicating that T cells can contribute to the control of RRV infection in the absence of B cells and 
antibody. Collectively, these data demonstrate a role for T cells in the control of RRV infection 
and suggest that the antiviral capacity of T cells is controlled in a tissue-specific manner.
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Ross River virus (RRV), chikungunya virus (CHIKV), and several related viruses are 
mosquito-transmitted, positive-sense, single-stranded RNA viruses in the Alphavirus genus 
of the Togaviridae family that cause a debilitating musculoskeletal inflammatory disease in 
humans (1). These globally distributed viruses cause endemic disease and, occasionally, 
large epidemics. In 1979–1980, RRV spread from Australia to multiple islands in the Pacific 
Region, including Fiji, the Cook Islands, and America Samoa, resulting in more than 60,000 
cases (2–5). After several decades of relative absence, CHIKV re-emerged in both Africa 
and Asia, causing large outbreaks and becoming a substantial global public health concern 
(6). Due to international travel, imported CHIKV cases have been reported in nearly 40 
countries including the USA, Japan, and several European countries. In addition, local 
transmission of CHIKV has been documented for the first time in several locations, 
including Italy, France, New Caledonia, Papua New Guinea, and Yemen (7–11). Most 
recently, autochthonous transmission of CHIKV has occurred for the first time in the W. 
Hemisphere, with over 750,000 confirmed and suspected cases reported from a number of 
Caribbean islands as well as a few countries in Central America and in South America (12, 
13).
The hallmark clinical manifestation following infection with arthritogenic alphaviruses is 
severe polyarthralgia that mainly affects the peripheral small joints (1, 14–16). Other 
classical symptoms include the sudden onset of fever, myalgias, an impaired ability to 
ambulate, and sometimes rash (1, 17). Surveys conducted for RRV-infected patients have 
shown that symptoms for most patients progressively resolve over 3–6 months (16). Up to 
60% of persons infected with CHIKV complain of musculoskeletal pain for months to years, 
although the cause of these long-lasting symptoms is unclear (1, 17). Atypical outcomes of 
CHIKV infection occur and include neurologic manifestations, myocarditis, and death; these 
outcomes are associated with age and underlying medical conditions (18). There are 
currently no licensed antivirals or vaccines for any of the arthritogenic alphaviruses; 
treatment is limited to supportive care with analgesics and anti-inflammatory drugs (19).
A number of studies have identified the importance of the host innate immune responses, 
particularly the type I IFN response, for controlling arthritogenic alphavirus infections (20–
28). In addition, studies in humans and animal models have demonstrated that antibodies are 
important mediators of protection. In humans, the early appearance of anti-CHIKV IgG3 
antibodies was associated with efficient virus clearance from the serum (29). Similarly, 
CHIKV-infected Rag1−/−, Rag2−/−, and Ighm−/− mice, but not Cd4−/− or Cd8−/− mice, have 
increased and sustained viremia, further supporting an important role for antibodies in 
clearance of virus from the serum (30–32). In addition, prophylaxis via passive transfer of 
human or murine immune serum, virus-specific IgG, or virus-specific monoclonal 
antibodies to highly susceptible Ifnar1−/− mice or WT mice can protect against RRV or 
CHIKV-induced mortality and musculoskeletal disease (31, 33–40). The importance of 
antibodies during alphavirus infection was also demonstrated in studies in mice with 
neurotropic Sindbis virus (SINV), which showed that antibody is important for the clearance 
of infectious virus (41), although replication competent RNA remained for months after 
antibody treatment in SINV-infected immunodeficient SCID mice (42).
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In contrast to the role of antibodies, the kinetics of T cell activation and the role of T cells in 
the control of alphavirus infection in musculoskeletal tissues are poorly defined. During 
acute CHIKV infection in humans and macaques, an increase in activated peripheral T cells 
has been reported (43–45). Additionally, it was recently shown that CD4+ and CD8+ T cells 
from CHIKV-infected patients produce IFN-γ in response to several CHIKV antigens, with 
responses against E2 being the highest in magnitude (46). T cells are also an important 
component of the inflammatory infiltrate: T cells have been found in synovial fluid as well 
as synovial and muscle tissue biopsies collected from RRV- and CHIKV-infected patients 
(44, 47, 48). Consistent with these findings, studies in RRV- and CHIKV-infected mice have 
shown that CD4+ and CD8+ T cells infiltrate infected muscle and joint tissue (49–52). In 
mice, CD4+ T cells were shown to contribute to CHIKV-induced foot swelling and 
musculoskeletal tissue injury (32); however, the extent to which either CD4+ or CD8+ T 
cells contribute to the control and clearance of alphavirus infections in musculoskeletal 
tissues has not been investigated. T cells are critical for the clearance of viral RNA from 
central nervous system tissues of mice infected with neuroadapted SINV (53–55), and RRV-
specific CD8+ T cells derived from previously infected mice mediated clearance of RRV 
from persistently-infected macrophages in vitro (56), suggesting that T cells may contribute 
to controlling arthritogenic alphavirus infections in vivo.
In this study, utilizing a relevant mouse model of arthritogenic alphavirus-induced 
rheumatological disease (49), we sought to characterize the kinetics of the CD8+ T cell 
response and investigate the role of CD8+ T lymphocytes in the control of arthritogenic 
alphavirus infection in musculoskeletal tissues. To investigate antigen-specific CD8+ T cell 
responses, we generated a recombinant RRV expressing the CD8 (gp33-41) 
immunodominant epitope of the well-studied lymphocytic choriomeningitis virus (LCMV). 
Utilizing this system, we found that RRV infection induces virus antigen-specific CD8+ T 
cell responses, characterized by expansion, modulated expression of cell surface proteins 
associated with activation, and cytokine production, in both lymphoid and musculoskeletal 
tissues. Furthermore, we found that CD8α−/− mice and mice depleted of CD8+ T cells had 
significantly increased viral RNA levels in muscle tissue compared to control mice. 
Remarkably, the levels of viral RNA in joint-associated tissues was unaffected by genetic 
deletion or antibody-mediated depletion of CD8+ T cells. Consistent with these data, 
Rag1−/− mice reconstituted with CD8+ and CD4+ T cells had significantly decreased viral 
loads in muscle tissue but not joint-associated tissue, suggesting that T cells can contribute 
to viral control in the absence of B cells and antibody. These studies provide important new 
insights into the CD8+ T cell response during arthritogenic alphavirus infection.
MATERIALS AND METHODS
Ethics Statement
All mouse studies were performed in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All 
mouse studies were performed at the University of Colorado Anschutz Medical Campus 
(Animal Welfare Assurance #A 3269-01) using protocols approved by the University of 
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Colorado Institutional Animal Care and Use Committee. All studies were performed in a 
manner designed to minimize pain and suffering in infected animals.
Viruses
The T48 stain of RRV was isolated from Aedes vigilax mosquitoes in Queensland, Australia 
(57). Prior to cDNA cloning, the virus was passaged 10 times in suckling mice, followed by 
two passages on Vero cells (58, 59). Lymphocytic choriomeningitis virus (LCMV) 
Armstrong (clone 53b) was originally obtained from Dr. M. Oldstone, and stocks were 
prepared by a single passage on BHK-21 cells. Plaque assays for determination of LCMV 
titers were performed as previously described (60).
The recombinant “RRV-LCMV” was generated by inserting a tandem sequence, similar in 
design to a sequence inserted in the influenza virus genome that encodes the LCMV CD8 T 
cell receptor epitope gp33-41 (KAVYNFATC) and CD4 T cell receptor epitope gp61–80 
(GLKGPDIYKGVYQFKSVEFD) (61) in-frame with the RRV structural polyprotein. The 
LCMV peptides were linked to 19 amino acids of the 2A protease of foot-and-mouth disease 
virus (FMDV), and this entire sequence was synthesized by Genewiz. A plasmid encoding 
the full-length T48 cDNA clone along with green fluorescent protein in-frame (pGH1.2) 
(kindly provided by Mark T. Heise, University of North Carolina) was mutagenized at RRV 
nucleotide 6476 to remove an ApaI restriction enzyme site. The pGH1.2ΔApa16476 plasmid 
was digested with AgeI to release a 1426 base pair (bp) AgeI-AgeI fragment. The vector 
lacking this fragment was religated (pGH1.2ΔApaI6476.1), which created a vector with a 
single ApaI and single AgeI site. The pGH1.2ΔApaI6476.1 plasmid was digested with AgeI 
and ApaI and ligated with the AgeI-ApaI–digested Genewiz construct. The AgeI-AgeI 
fragment was re-inserted and screened for directionality, resulting in the LCMV and FMDV 
2A protease sequences inserted in-frame between the capsid and E3 genes of RRV. During 
replication, the LCMV-2A fusion protein is synthesized as a component of the viral 
structural polyprotein that is then released by intramolecular cleavages mediated by the 
RRV capsid and FMDV 2A proteases. Stocks of infectious RRV-LCMV and RRV were 
generated from cDNAs and titered by direct plaque assay on BHK-21 cells as previously 
described (62).
Mice
C57BL/6 wild-type (stock # 000664), Rag1−/− (stock # 002216), and CD8α−/− (stock # 
002665) mice were obtained from The Jackson Laboratory and bred in house. Animal 
husbandry and experiments were performed in accordance with all University of Colorado 
School of Medicine Institutional Animal Care and Use Committee guidelines. All mouse 
studies were performed in an animal biosafety level 3 laboratory. For LCMV infections, six-
to-ten week-old mice were inoculated with 2 × 105 PFU via the intraperitoneal (i.p.) route 
and monitored daily. For RRV infection, three-to-four week old mice were used. In contrast 
to older mice in which RRV replication and dissemination is restricted, three-to-four week 
old mice develop a disseminated infection and musculoskeletal disease signs similar to RRV 
disease in humans (63). Mice were inoculated in the left rear footpad with 103 PFU of wild-
type RRV or RRV-LCMV in diluent (PBS/1% bovine calf serum) in a 10-μl volume. Mock-
infected animals received diluent alone. Mice were monitored for disease signs and weighed 
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at 24-h intervals. Disease scores were determined by assessing grip strength, hind limb 
weakness, and altered gait, as previously described (49). On the termination day of each 
experiment, mice were sacrificed by exsanguination, blood was collected, and mice were 
perfused by intracardial injection of 1x PBS. PBS-perfused tissues were removed by 
dissection and homogenized in TRIzol Reagent (Life Technologies) for RNA analysis with a 
MagNA Lyser (Roche). Alternatively, quadriceps muscles were dissected, minced, and 
incubated for 1.5 h with vigorous shaking at 37°C in digestion buffer (RPMI 1640, 10% 
FBS, 15 mM HEPES, 2.5 mg/ml Collagenase Type 1 [Worthington Biochemical], 1.7 
mg/ml DNase I [Roche], 1x gentamicin [Life Technologies], 1% penicillin/streptomycin). 
Following digestion, cells were passed through a 100-μm cell strainer (BD Falcon) and 
banded on Lympholyte-M (Cedarlane Laboratories) to isolate infiltrating leukocytes. 
Additionally, spleens and draining popliteal lymph nodes were dissected from mice and 
passed through a 100-μm cell strainer. Following red blood cell lysis (spleens only), cells 
were washed in wash buffer (1x PBS, 15 mM HEPES, 1x gentamicin, 1% penicillin/
streptomycin), and total viable cells were determined by trypan blue exclusion. Sera samples 
were titered by direct plaque assay on BHK-21 cells.
Flow cytometry and adoptive transfer
Leukocytes isolated from enzymatically digested tissues were incubated with anti-mouse 
FcγRII/III (2.4G2; BD Pharmingen) for 20 min on ice to block nonspecific Ab binding and 
then stained in FACS staining buffer (1x PBS, 2% FBS) with the following Abs: anti-CD3-
fluorescein isothiocyanate (FITC, clone 145-2C11), anti-CD3-allophycocyanin (APC, 
145-2C11), anti-CD4-Pacific Blue (RM4-5), anti-CD8α-phycoerythrin (PE, 53-6.7), anti-
CD44-PE-Cy7 (IM7), anti-CD62L-PE-Cy7 (MEL-14), anti-TNF-α-FITC (MP6-XT22), 
anti-IFN-γ-PE-Cy7 (XMG1.2), anti-IL-2-APC (JES6-5H4), anti-B220-PE-Cy7 (RA3-6B2), 
and anti-CD19-FITC (6D5) (all from BioLegend); anti-CD8β-PE (H35-17.2), anti-CD11b-
APC (M1/70), anti-F4/80-FITC (BM8), and anti-Gr-1-PE-Cy7 (RB6-8C5) (all from 
eBioscience). gp33-APC H-2Db KAVYNFATM tetramer was kindly provided by the 
National Institutes of Health Tetramer Core Facility. Cells were fixed overnight in 1% 
paraformaldehyde and analyzed on an LSR II using FACSDiva software (Becton 
Dickinson). Further analysis was done using FlowJo Software (Tree Star). Doublets were 
excluded using forward-scatter height and width parameters.
For intracellular cytokine analysis, spleen cells from Rag1−/− mice were used as antigen 
presenting cells (APCs) and pulsed with or without 1 μg of gp33 peptide per 5 × 106 APCs 
for 1 h at 37°C in RPMI containing 7% FBS. Muscle-infiltrating leukocytes from RRV-
LCMV-infected mice were isolated at 10 dpi. 0.5 × 106 APCs (pulsed with or without gp33 
peptide) per well were added to a 96 well round-bottom plate in 100 μl RPMI containing 7% 
FBS and Brefeldin A followed by addition of muscle-infiltrating leukocytes in 100 μl RPMI 
containing 7% FBS. Cells were incubated together for 5 h in the presence of Brefeldin A to 
prevent cytokine release. Cells were harvested, and incubated with anti-mouse FcγRII/III 
(2.4G2) for 20 min on ice followed by surface marker staining in FACS buffer for an 
additional 20 min on ice. After one wash step, cells were fixed and permeabilized in a 1% 
paraformaldehyde and saponin solution for 15 min at room temperature. Cells were washed 
with PBS containing saponin and then stained for intracellular cytokines for 45 min on ice in 
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PBS with saponin. Finally, cells were washed 1X with PBS containing saponin, 1X with 
FACS buffer, and then fixed overnight in 1% paraformaldehyde. Muscle-infiltrating 
leukocytes from WT RRV-infected mice and splenocytes from a LCMV Armstrong-infected 
mouse were used as controls for the specificity of restimulation.
For T cell adoptive transfer experiments, CD4 plus CD8 T cells or CD8 T cells alone were 
isolated from the spleens of naïve wild-type C57BL/6 mice via negative selection using a 
pan-T cell isolation kit or CD8 T cell isolation kit, respectively (Miltenyi Biotec). Following 
isolation, cells were counted and 2.5 × 106 CD4 plus CD8 T cells or 1 × 106 CD8 T cells 
were resuspended in RPMI containing 2% FBS in a total volume of 200 μl for i.p. injection 
into Rag1−/− mice one day prior to RRV infection. Control Rag1−/− mice received 200 μl of 
media alone. Of the transferred T cells, ≥ 95% of the cells were CD3+. In the pan T cell 
groups, ~60% of the CD3+ T cells were CD4+ and ~35% were CD8+; in the CD8 T cell 
groups, ≥ 95% of the CD3+ T cells were also CD8+. Additionally, ≤ 1% of CD19+ B cells 
remained in the injected cell preparations. T cell transfer was confirmed by flow cytometric 
analysis of spleen and muscle tissue at 14 dpi as described above for the presence of cells 
staining negatively for B220 (RA3-6B2) and Gr-1 (RB6-8C5) and positively for CD3 
(145-2C11) and CD4 (RM4-5) or CD8α (53–6.7).
Quantitative RT-PCR
RNA was isolated using a PureLink RNA Mini Kit (Life Technologies). Absolute 
quantification of viral RNA was performed as previously described (62). Briefly, a 
sequence-tagged (small caps) RRV-specific RT primer (4415-5'-
ggcagtatcgtgaattcgatgcAACACTCCCGTCGACAACAGA-3') was used for reverse 
transcription. A tag sequence-specific reverse primer (5'-
GGCAGTATCGTGAATTCGATGC-3') was used with an RRV sequence-specific forward 
primer (4346 5'-CCGTGGCGGGTATTATCAAT-3') and an internal TaqMan probe (4375 
5'-ATTAAGAGTGTAGCCATCC-3') during qPCR to enhance specificity. To create 
standard curves, 10-fold dilutions, from 108 to 100 copies of RRV genomic RNAs, 
synthesized in vitro, were spiked into RNA from BHK-21 cells, and reverse transcription 
and qPCR were performed in an identical manner.
Histological analysis
At 10 dpi, mice were sacrificed and perfused by intracardial injection of 1X PBS, and the 
left gastrocnemius muscle was dissected and fixed in 4% paraformaldehyde (pH 7.3). 
Tissues were embedded in paraffin, and 5-μm sections were prepared. To assess the degree 
of tissue inflammation, tissue sections were stained with H&E and evaluated by light 
microscopy by a trained pathologist. Each section was scored in a blinded manner using the 
following scoring system: 0, absent; 1, minimal, <10% of tissue affected; 2, mild, 10–24% 
of tissue affected; 3, moderate, 25–39% of tissue affected; 4, marked, 40–59% of tissue 
affected; 5, severe, >60% of tissue affected.
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Creatine Kinase Activity Assay
Creatine kinase activity in the serum of mock- and RRV-inoculated mice was determined by 
utilizing a colorimetric assay; the manufacturer's instructions were followed (Stanbio 
Laboratory).
Statistical Analysis
All data were analyzed using GraphPad Prism 5 software. Data were evaluated for 
statistically significant differences using either a two-tailed, unpaired t-test with or without 
Welch's correction, a one-way analysis of variance (ANOVA) test followed by Tukey's 
multiple comparison test, or a two-way ANOVA followed by a Bonferroni multiple 
comparison test. A P-value < 0.05 was considered statistically significant. All differences 
not specifically indicated to be significant were not significant (P > 0.05).
RESULTS
RRV-infected Rag1−/− mice have increased viral loads in musculoskeletal tissues
Previous studies in mice suggested that the adaptive response is dispensable for the 
development of acute RRV-induced musculoskeletal clinical disease signs (49, 64) and for 
control of acute RRV infection (65). To evaluate a role for the adaptive immune response at 
later times post-infection, we quantified viral RNA loads in the quadriceps muscle and ankle 
tissue at 7 and 14 dpi of RRV-inoculated WT and Rag1−/− mice which lack functional T and 
B lymphocytes (66). RRV-inoculated Rag1−/− mice had significantly higher viral loads in 
both muscle tissue (13.8-fold increase, P < 0.001) and joint tissue (6-fold increase, P < 
0.001) at 7 dpi and at 14 dpi (quadriceps: 31.7-fold increase, P < 0.001; ankle: 34.5-fold 
increase, P < 0.001) (Figure 1A and B). These data suggest that the adaptive immune 
response is important for the control of RRV infection.
Recombinant RRV-LCMV behaves similarly to WT virus in vitro and in vivo
Our experiments in Rag1−/− mice did not distinguish the role of T versus B lymphocytes in 
controlling RRV infection. Several studies have evaluated the role of antibodies in control of 
arthritogenic alphavirus infection; however, the role of T cells in control of these infections 
is less clear. Due to the availability of reagents such as tetramers and TCR transgenic mice 
that recognize LCMV-specific T cells and epitopes, respectively, previous groups have 
generated recombinant viruses that express the immunodominant CD8 (gp33) and/or CD4 
(gp61) epitopes of LCMV to investigate antigen-specific T cell responses during infection 
(61, 67, 68). To take advantage of these immunological tools, we generated a recombinant 
Ross River virus that contains a tandem sequence encoding the gp3333-41 and gp6161–80 
peptides (61) in-frame with the RRV structural polyprotein, termed “RRV-LCMV” (Figure 
2A). Specifically, the LCMV peptide sequences were linked to 19 amino acids of the 2A 
protease of foot-and-mouth disease virus (FMDV) and then inserted in-frame between the 
capsid and E3 genes of RRV. During replication, the LCMV-2A fusion protein is 
synthesized as a component of the viral structural polyprotein that is then released by 
intramolecular cleavages mediated by the RRV capsid and FMDV 2A proteases. This design 
was selected based on previous studies indicating that insertion of foreign sequences into 
Burrack et al. Page 7






















alphavirus genomes in this manner results in minimal attenuation and enhanced genome 
stability (69, 70). An in vitro multistep growth curve was performed to compare WT RRV 
and RRV-LCMV growth in BHK-21 cells. Importantly, yields of infectious RRV-LCMV 
were similar to WT RRV at all time points (Figure 2B). We next compared the outcome of 
infection in vivo. Three-to-four week old C57BL/6 mice inoculated with RRV-LCMV 
gained significantly more weight than WT RRV-inoculated mice on days 7–10 pi, indicating 
some degree of attenuation of the recombinant virus (Figure 2C), as expected from previous 
studies utilizing this design (69, 70). However, musculoskeletal disease scores for RRV-
LCMV-inoculated mice during the acute stage were not significantly different from WT 
RRV-inoculated mice (Figure 2D). To further compare RRV-induced disease, viral loads 
from mice inoculated with WT RRV and the recombinant RRV-LCMV were quantified 5 
and 10 dpi in muscle (Figure 2E) and joint-associated tissues (Figure 2F). Viral loads in 
muscle tissue were similar at 5 dpi, although RRV-LCMV-infected mice had significantly 
reduced viral loads at 10 dpi compared to WT RRV-infected mice (8.9-fold decrease, P = 
0.02) (Figure 2E), suggesting that the recombinant RRV-LCMV is cleared more efficiently. 
However, viral loads in ankle tissue of RRV-LCMV-inoculated mice were similar to WT 
RRV-inoculated mice at 10 dpi and slightly lower, albeit statistically significant, at 5 dpi, 
(Figure 2F). Consistent with these data, WT RRV and RRV-LCMV induced similar muscle 
inflammation and tissue damage during the acute phase of disease as seen in representative 
images of H&E-stained tissue sections derived from gastrocnemius muscle tissue at 10 dpi 
(Figure 2G), which were scored for the level of inflammation by a blinded pathologist 
(Figure 2H). Additionally, similar levels of creatine kinase activity, which is a marker of 
muscle tissue damage, were measured in sera from mice inoculated with WT RRV and 
RRV-LCMV at 7 and 10 dpi, the peak of acute disease (Figure 2I). Overall, these data 
demonstrate that the recombinant RRV-LCMV virus behaves similarly to WT RRV in cell 
culture and in mice.
RRV infection induces virus antigen-specific T cells responses in lymphoid and 
musculoskeletal tissues
One value of the recombinant RRV-LCMV is that it allows the kinetics of virus-specific 
CD8+ T cell responses to be investigated via gp33 tetramer staining of isolated cell 
populations. Mice were inoculated with 103 PFU of RRV-LCMV and spleens, draining (left) 
popliteal lymph nodes, and quadriceps muscle tissues were taken at 5, 7, 10, and 14 dpi for 
analysis of gp33-specific CD8+ T cells. WT RRV-infected mice (10 dpi) and LCMV-Arm-
infected mice (7 dpi) were used as negative and positive controls for gp33 tetramer staining, 
respectively. After gating on lymphocytes and excluding doublets (Fig. S1A), the gp33-
specific CD8+ T cell population was quantified by gating on CD8+CD4− T cells followed by 
gating on gp33 tetramer-positive cells (Figure 3A and Fig. S1B). This gp33 tetramer-
positive gate was set such that there were ≤ 0.1% of gp33+ cells from the CD8+CD4− 
population from mock or WT RRV-infected control samples for each tissue. Utilizing this 
gating scheme, we identified a small number of gp33-specific CD8+ T cells in lymphoid and 
muscle tissues of RRV-LCMV-infected mice starting at day 5 pi (Figure 3B and C and Fig. 
S1B). These virus-specific CD8+ T cells expanded, and a distinct population was readily 
detectable in both the spleen and muscle tissue at 7 and 10 dpi. By 14 dpi, abundant gp33-
specific CD8+ T cells were still present but in diminished numbers in all tissues analyzed. 
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These data demonstrate that RRV infection in mice induces a virus-specific CD8+ T cell 
response and that these cells traffic to the sites of infection. Of note, a significantly increased 
percentage of CD8+ T cells was identified in the spleen and muscle tissue, but not the pLN, 
of RRV-LCMV-infected mice compared to WT RRV-infected mice (spleen, P = 0.008; 
muscle, P = 0.003); however, the total number of CD8+ T cells were not significantly 
different in either tissue (Figure 3B). These data suggest that expression of the 
immunodominant gp33 epitope stimulated an increased CD8+ T cell response in mice 
infected with the recombinant RRV-LCMV compared to mice infected with WT RRV, 
although this did not affect the total CD8+ T cell numbers in the tissues.
To determine the activation status of the virus-specific CD8+ T cells, we analyzed cell 
surface expression of T cell activation markers on gp33+CD8+ T cells from the spleen and 
muscle tissue during the peak of acute disease at 10 dpi, compared to mock splenocytes or 
splenocytes from a LCMV-Arm-infected mouse (7 dpi) (Figure 4A). CD44 is an adhesion 
molecule that is upregulated on antigen-experienced T cells (71). As expected, nearly 100% 
of the gp33+CD8+ T cells in the spleen of RRV-LCMV-infected mice were CD44+ at 10 dpi 
(Figure 4B). In contrast, on average, 16.5% of the muscle-infiltrating gp33+CD8+ T cells 
were negative for CD44. We also analyzed cell surface expression of CD62L, which is a 
lymph node homing receptor that is downregulated following antigen stimulation (71). As 
expected, very few of the spleen or muscle-infiltrating gp33+CD8+ T cells stained for 
CD62L (Figure 4B). Due to the lack of CD44 staining on a percentage of muscle-infiltrating 
virus antigen-specific CD8+ T cells, we also investigated the CD44 staining on all CD8+ T 
cells in the muscle and spleen of both WT RRV-and RRV-LCMV-infected mice at 10 dpi. 
Here, we found about 24% of total CD8+ T cells in the muscle tissue did not stain for CD44, 
either when mice were infected with WT RRV or RRV-LCMV (Figure 4C and D). In 
contrast, significantly more total CD8+ T cells in the spleens of RRV-LCMV-infected mice 
were CD44+ than CD8+ T cells in the spleens of WT RRV-infected mice (67% versus 57%, 
P = 0.002) (Figure 4C and D), suggesting slightly increased CD8+ T cell activation in RRV-
LCMV-infected mice, potentially due to expression of the immunodominant gp33 epitope. 
In addition, we quantified CD62L expression on total CD8+ T cells in the spleen and muscle 
tissues of WT RRV- and RRV-LCMV-infected mice; in this case, no significant differences 
were identified (Figure 4C and D). Overall, these data indicate that the CD8+ T lymphocyte 
response to the recombinant RRV-LCMV is very similar to WT RRV.
In addition to T cell activation markers, we investigated the functionality of the virus-
specific CD8+ T cells by determining expression levels of multiple cytokines in response to 
peptide stimulation. At 10 dpi, muscle-infiltrating leukocytes were isolated and restimulated 
ex vivo with or without gp33 peptide for 5 hours in the presence of Brefeldin A, followed by 
surface staining for CD4 and CD8 and intracellular cytokine staining for IFN-γ, TNF-α, and 
IL-2. Muscle-infiltrating leukocytes from WT RRV-infected mice and splenocytes from a 
LCMV-Arm-infected mouse were used as controls for the specificity of peptide 
restimulation. As shown in Figure 4E, cells incubated with APCs only (no peptide) showed 
minimal cytokine production (≤ 1% in any cytokine group). Similarly, muscle-infiltrating 
CD8+ T cells from WT RRV-infected mice did not produce cytokines after gp33 peptide 
restimulation. In contrast, about one third of the muscle-infiltrating CD8+ T cells from RRV-
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LCMV-infected mice produced TNF-α and/or IFN-γ after gp33 restimulation, with the 
majority of cytokine-producing cells secreting both TNF-α and IFN-γ (Figure 4E–G). These 
double-producing cells were also analyzed for IL-2 production. Figure 4F shows a pie chart 
illustrating the division of muscle-infiltrating, cytokine-expressing CD8+ T cells into single-
positive, double-positive, and triple-positive groups. The average percentages were as 
follows: TNF-α+ (4.7%), IFN-γ+ (8.4%), TNF-α+IFN-γ+ (20.8%), and TNF-α+IFN-γ+IL-2+ 
(2.4%). These data demonstrate that cytokine-producing, virus-specific CD8+ T cells are 
present in skeletal muscle tissue, a major site of infection and injury during infection with 
arthritogenic alphaviruses.
CD8+ T cells contribute to control of acute RRV infection
Based on our observations that muscle-infiltrating, virus-specific CD8+ T cells were 
activated and produced cytokines following ex vivo analysis, we hypothesized that CD8+ T 
cells contribute to the control of RRV infection. To investigate this hypothesis, WT and 
CD8α−/− mice were inoculated with 103 PFU of RRV, and skeletal muscle and ankle joint 
tissues were harvested at 7 and 14 dpi for analysis of RRV RNA levels via absolute RT-
qPCR. CD8α−/− mice had similar viral loads to WT mice at 7 dpi in muscle tissue (Figure 
5A). CD8α−/− mice had slightly lower viral loads, albeit significant, than WT mice at 7 dpi 
in joint tissue (2.7-fold decrease, P < 0.05) (Figure 5B). In contrast, CD8α−/− mice had 
significantly increased viral loads in quadriceps muscle tissue at 14 dpi (9.8-fold increase, P 
< 0.001) and 21 dpi (5.4-fold increase, P < 0.01) (Figure 5A). CD8α−/− mice had similar 
viral loads to WT mice in the ankle joint tissue at 14 dpi but slightly greater viral loads at 21 
dpi in this tissue (2.7-fold increase, P < 0.05) (Figure 5B). These data suggest that CD8+ T 
cells more effectively control RRV infection in muscle tissue compared to joint-associated 
tissues. WT and CD8α−/− mice had similar serum viremia levels at 3 dpi (data not shown). 
Additionally, RRV-infected CD8α−/− mice had similar weight gain and disease scores as 
infected WT mice (Figure 5C and D), suggesting that the loss of CD8+ T cells results in a 
similar acute disease course.
The findings in CD8α−/− mice were confirmed by antibody-mediated depletion studies. 
RRV-inoculated WT mice were treated with an anti-CD8α antibody or an isotype control 
antibody at 7 and 12 dpi, and muscle and joint tissues were harvested at 14 dpi for 
quantification of RRV RNA levels. The anti-CD8α antibody treatments effectively depleted 
CD8+ T cells as determined by flow cytometric analysis of splenocytes from control 
antibody- or anti-CD8α antibody-treated mice at 14 dpi for the surface markers CD3 and 
CD8β (Figure 6A and B). As with CD8α−/− mice, anti-CD8α antibody-treated mice had 
significantly increased viral loads in quadriceps muscle (17.3-fold increase, P = 0.0014) but 
not ankle joint tissue at 14 dpi (Figure 6C and D). These findings suggest that while CD8+ T 
cells contribute to viral control in muscle tissue they play a limited role in joint tissue of WT 
mice following RRV infection.
Adoptive transfer of CD8+ and CD4+ T cells reduces RRV infection in Rag1−/− mice
To test whether T cells are sufficient to control RRV infection in the absence of B cells or 
antibody, we performed adoptive transfer experiments of T cells into Rag1−/− mice. Pan T 
cells were isolated via negative selection from the spleens of adult WT C57BL/6 mice. 
Burrack et al. Page 10






















Rag1−/− mice received 2.5 × 106 T cells i.p. and were inoculated with RRV 24 hours later. 
Muscle and joint tissues were harvested for RRV RNA analysis at 14 dpi. Additionally, T 
cell transfer was confirmed by flow cytometric analysis of spleen and quadriceps muscle 
tissue at 14 dpi for the presence of cells staining positively for CD3, CD4, and CD8 and 
negatively for B220 and Gr-1 (Figure 7A–C). T cell engraftment varied between the mice, 
but T cells could be identified in the spleen and muscle tissue of all mice (Figure 7B and C). 
RRV RNA levels were significantly lower in muscle tissue of mice that received T cells 
compared to mice that received media (5.3-fold decrease, P < 0.001) (Figure 7D). 
Additionally, T cell transfer decreased viremia in most of the mice although the difference 
did not reach statistical significance (P > 0.05) (Figure 7E). Moreover, the mice that had the 
best T cell engraftment also had the lowest RNA levels; that is, viral loads correlated 
significantly with the percent of CD3+ T lymphocytes found in the spleen (r2 = 0.79, P < 
0.0001) (Figure 7F) and quadriceps muscle tissue (r2 = 0.70, P = 0.0002) (Figure 7G) as 
well as the total number of T cells found in both tissues (spleen: r2 = 0.44, P = 0.0095; 
muscle: r2 = 0.50, P = 0.0045) (data not shown). Consistent with our results in CD8α−/− 
mice and CD8-depleted WT mice, adoptively transferred T cells did not reduce viral loads in 
the ankle tissue of Rag1−/− mice (data not shown). To determine if CD8+ T cells could 
decrease RRV RNA levels independent of CD4+ T cell help, we adoptively transferred 1 × 
106 naïve CD8+ T cells into Rag1−/− mice one day prior to RRV inoculation. We found that 
naïve CD8+ T cells had no effect on RRV RNA levels at 14 dpi (Figure 7D), suggesting that 
naïve CD8+ T cells require CD4+ T cell help to control RRV infection. Further studies are 
needed to determine if RRV-immune CD8+ T cells can control RRV infection in the absence 
of CD4+ T cell help.
DISCUSSION
Although type I IFN is critical for controlling alphavirus infection (1, 23, 72), 
epidemiological evidence suggests that arthritogenic alphavirus infection results in lifelong 
protective immunity (73), indicating a role for the adaptive immune response. Indeed, 
antibodies are considered important mediators of protection against arthritogenic 
alphaviruses (33, 74, 75). Consistent with this, we recently demonstrated that CHIKV-
infected Rag1−/− mice have significantly increased viral RNA levels in inflamed 
musculoskeletal tissues for weeks after inoculation (31). Similarly, here we show that RRV-
infected Rag1−/− mice have significantly higher viral loads in both muscle and joint tissue at 
7 and 14 dpi (Figure 1). In this study, we sought to elucidate the role for T cells, specifically 
CD8+ T cells, in the control of arthritogenic alphavirus infection in musculoskeletal tissues.
Previous publications have demonstrated that both CD4+ and CD8+ T cells are a major 
component of the muscle-infiltrating leukocytes starting at day 5 post-RRV infection (49, 
50, 76). Additionally, an early report on RRV infection in mice showed virus-specific T cell 
proliferation when exposed to virus ex vivo (77), and a recent report on CHIKV infection in 
mice demonstrated that spleen and footpad-infiltrating T cells could produce IFN-γ after ex 
vivo stimulation with virus (32). Additionally, several studies have shown virus-specific T 
cell responses following immunization with different CHIKV vaccines in mouse and 
macaque models (36, 78), indicating an expansion and activation of virus-specific T cells. 
However, the kinetics of virus-specific T cell responses in mice and the role of T cells in the 
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control of infection in musculoskeletal tissues have not been evaluated. To identify virus 
antigen-specific T cells in C57BL/6 mice, we generated a recombinant Ross River virus that 
encodes the major MHC-I and MHC-II-restricted LCMV determinants, gp33 and gp61, in 
tandem (Figure 2), similar to a system recently utilized to study the virus-specific T cell 
response to influenza virus in mice (61). Using the recombinant RRV-LCMV we detected 
virus-specific CD8+ T cells in lymphoid tissues as well as inflamed musculoskeletal tissues 
of RRV-infected mice (Figure 3). Small numbers of virus-specific CD8+ T cells were 
detectable at 5 dpi in lymphoid and musculoskeletal tissues which expanded at 7 and 10 dpi 
and began to contract by 14 dpi. These data are consistent with previous reports on the 
kinetics of total T cell activation in CHIKV-infected mice and macaques (32, 45). 
Subsequent work will analyze CD4+ T cell immunity utilizing the recombinant RRV-
LCMV.
As expected, nearly all of the virus-specific CD8+ T cells in the spleen and muscle 
uniformly down-regulated the lymph node-homing molecule CD62L to aid in peripheral 
homing (Figure 4). Also anticipated was that nearly all of the virus-specific CD8+ T cells in 
the spleen at 10 dpi were CD44+ since it is a marker of antigen-experienced T cells (71). 
However, approximately 15–20% of the virus-specific CD8+ T cells in the muscle tissue at 
10 dpi were CD44 low or negative. We previously reported that macrophages in the sites of 
infection and inflammation have immunosuppressive activity (62). The lack of CD44 
staining on a portion of the virus-specific CD8+ T cells suggests that the inflamed, 
immunosuppressive microenvironment within the muscle tissue may inhibit some aspect of 
T cell activation. We further found that a subset of total CD8+ T cells in the muscle tissue of 
WT RRV- and RRV-LCMV-infected mice did not stain for CD44, indicating that this 
differential CD44 expression was not particular to gp33-specific CD8+ T cells. The absence 
of CD44 staining could play an important role in T cell-mediated control of RRV infection 
since CD44 expression on T cells is important for trafficking to and within sites of 
inflammation (79). Additionally, downregulation of CD44 on virus-specific CD8+ T cells 
has been observed under conditions of chronic LCMV infection (80); this may also be 
occurring following infection with arthritogenic alphaviruses, which cause persistent 
infections in humans and animals (1, 16, 17, 31).
Following ex vivo peptide restimulation we found that a small portion of the virus-specific 
CD8+ T cells produced IFN-γ, TNF-α, and IL-2 (Figure 5). The majority of cytokine-
producing cells secreted both IFN-γ and TNF-α, followed by single IFN-γ-producers, then 
single TNF-α-producers. IL-2 production, although present, was minimal, with only 2–3% 
of all gp33-specific cells producing IL-2 (10% of IFN-γ+TNF-α+ cells). These findings are 
similar to previous analyses of cytokine-producing T cells in the CNS following infection 
with the neurotropic alphaviruses VEEV and SINV (81, 82). Irani and colleagues (82) found 
that IL-2 production by brain-infiltrating T cells was particularly deficient when compared 
with the levels made by stimulated spleen cells, suggesting that the local microenvironment 
regulates T cells that enter the brain. We did not evaluate cytokine production by spleen T 
cells from RRV-LCMV-infected mice in these studies; however, given the differences in 
activation marker staining between T cells in the spleen and muscle tissue of RRV-LCMV-
infected mice, we hypothesize that cytokine production by the muscle-infiltrating T cells 
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would be lower than spleen T cells due to the immunosuppressive environment within the 
inflamed muscle tissue (62).
Given that activated, virus-specific CD8+ T cells are present in infected musculoskeletal 
tissues of RRV-infected mice, we next sought to determine the contribution of CD8+ T cells 
in controlling RRV infection. A number of studies have shown that T cells can directly 
contribute to the control of alphavirus infection. Adoptive transfer of primed T cells but not 
antibody prevented lethal VEEV-induced encephalitis in TCRαβ−/− mice (83, 84). 
Furthermore, recovery from VEEV infection in μMT mice has been shown to be T cell-
dependent, with both CD8+ and CD4+ T cells contributing to control of VEEV replication 
systemically and in the CNS (81). Similarly, clearance of SINV RNA from the CNS of 
infected mice required both CD4+ and CD8+ T cells (54, 55). Consistent with these data, we 
found that mice depleted of CD8+ T cells as well as CD8α−/− mice had ~10-fold more RRV 
RNA in the muscle tissue than WT control mice at 14 dpi (Figures 5 and 6). Experiments in 
CD8α−/− mice infected with West Nile virus (WNV) demonstrated a clear role for CD8+ T 
cells in control of that positive-strand RNA virus infection. However, WNV-infected 
CD8α−/− mice had 1,000-fold more virus in the brain at 10 dpi than WT mice (85), which 
contrasts with the ~10-fold difference we detected following RRV infection of CD8α−/− 
mice versus WT mice at 14 dpi. These data suggest that although CD8+ T cells contribute to 
the control of RRV infection, their antiviral activities may be blunted in the inflamed, 
immunosuppressive microenvironment of the infected muscle tissue (62).
Tomov and colleagues (86) demonstrated that adoptive transfer of murine norovirus-specific 
CD8+ T cells into persistently infected Rag1−/− mice led to a significant reduction in viral 
loads that was dependent on the number of T cells transferred. Similarly, we found that T 
cells transferred into Rag1−/− mice one day prior to RRV infection reduced RRV RNA 
levels in muscle tissue by 14 dpi when compared to loads in Rag1−/− mice that received 
media, and the reduction in viral loads correlated with the frequency and total number of T 
cells present in the spleen and muscle tissue on the day of harvest (Figure 7). These data 
demonstrate that T cells control arthritogenic alphavirus infection in a relevant tissue – 
muscle tissue – in the absence of B cells and antibody. We further showed that adoptively 
transferred CD8+ T cells alone did not reduce RRV levels in muscle tissue of Rag1−/− mice 
(Figure 7). This occurred despite a similar number of CD8+ T cells in spleen and muscle 
tissue of mice that received CD8+ T cells alone compared to mice that received both CD4+ 
and CD8+ T cells. These data suggest that CD4 T cell-help is required for CD8+ T cell-
mediated control of RRV infection.
Interestingly, CD8α−/− mice, CD8+ T cell-depleted mice, and Rag1−/− mice that received 
adoptively transferred T cells had similar RRV RNA levels as control mice at 14 dpi in the 
ankle joint tissue (Figures 5 and 6, and data not shown), suggesting that T cells have 
minimal effects on virus control in joint tissue. This could be a result of i) inefficient 
migration into tissues, ii) inopportune location of target cells, iii) suppression of T cell 
antiviral functions in the joint, and/or a variety of other mechanism(s). Consistent with these 
data, Teo and colleagues (32) found that CD8−/− mice had similar levels of CHIKV RNA in 
the serum through day 12 pi, when the virus levels became undetectable, as well as similar 
joint swelling as CHIKV-infected WT mice. Additionally, mice depleted of CD8+ T cells 
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had similar viral loads in joint tissue as determined by luciferase intensity following 
infection with a recombinant Firefly luciferase-expressing CHIKV (32). These data, together 
with our findings, suggest that CD8+ T cells are ineffective at controlling arthritogenic 
alphavirus infection in joint tissues. Although T cell transfer resulted in a modest decrease in 
viremia for most mice (Figure 7E), this may not have reached statistical significance 
because of continued virus production from joint tissues. Overall, these data demonstrate an 
important but limited and tissue-specific role for CD8+ T lymphocytes in the control of 
pathogenic RRV infection.
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Figure 1. Rag1−/− mice have increased RRV loads compared to WT mice in musculoskeletal 
tissue at 7 and 14 dpi
Three-to-four week-old C57BL/6J WT (7 dpi, n = 6; 14 dpi, n = 6) and Rag1−/− (7 dpi, n = 
3; 14 dpi, n = 6) mice were inoculated with 103 pfu by injection into the left rear footpad. At 
7 and 14 dpi, mice were sacrificed, perfused by intracardial injection with 1x PBS, and total 
RNA was isolated from the (A) right quadriceps muscle and (B) right ankle/foot. RRV 
genomes were quantified by absolute RT-qPCR as described in the Materials and Methods. 
Horizontal bars indicate the mean. *** P < 0.001, as determined by one-way ANOVA 
followed by Tukey's multiple comparison test.
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Figure 2. Recombinant RRV-LCMV is similar to WT RRV in vitro and in vivo
(A) Schematic of recombinant RRV-LCMV virus encoding the CD8 (gp33) and CD4 (gp61) 
immunodominant epitopes of the LCMV glycoprotein. (B) BHK-21 cells were inoculated 
with a MOI of 0.01 PFU/cell of WT RRV or RRV-LCMV, and infectious virus in the 
supernatant was titered at 0 (inoculum), 1, 3, 6, 12, and 24 hpi by direct plaque assay on 
BHK-21 cells. Three-to-four week-old C57BL/6J WT mice were mock-inoculated (PBS) (n 
= 3) or inoculated with 103 PFU of WT RRV (n = 7) or RRV-LCMV (n = 15) and assessed 
for (C) weight gain and (D) musculoskeletal disease signs including loss of gripping ability 
and altered gait at 24-hour intervals. Each data point represents the arithmetic mean ± SEM. 
* P < 0.05 for days 7−10 pi between WT RRV and RRV-LCMV groups as determined by 
two-way ANOVA followed by a Bonferroni multiple comparison test. (E, F) Three-to-four 
week-old C57BL/6J WT mice were or inoculated with 103 PFU of WT RRV or RRV-
LCMV, and RRV genome levels in the right quadriceps muscle (E) and right ankle/foot (F) 
were analyzed by absolute RT-qPCR at 5 dpi (n = 4) and 10 dpi (n = 5). Horizontal bar 
represents the mean. * P = 0.02, ** P = 0.009, as determined by two-way, unpaired t-tests. 
(G) Five-μm paraffin-embedded sections were generated from the gastrocnemius muscles of 
mock (n = 2), WT RRV (n = 4), and RRV-LCMV (n = 5) infected mice at 10 dpi and H&E 
stained. (H) H&E-stained sections from 10 dpi were scored in a blinded manner for the 
degree of inflammation based on the following scale for the percentage of tissue affected: 0, 
absent (0%); 1, minimal (<10%); 2, mild (11–25%); 3, moderate (26–40%); 4, marked (41–
60%); and 5, severe (>60%). Graphs represent the arithmetic mean ± SEM. (I) Three-to-four 
week-old C57BL/6J WT mice were mock-inoculated (n = 6) or inoculated with 103 PFU of 
WT RRV (7 dpi, n =7; 10 dpi, n = 11) or RRV-LCMV (7 dpi, n = 11; 10 dpi, n = 12). At 7 
and 10 dpi, blood was collected for analysis of creatine kinase activity in the serum. Graphs 
represent the arithmetic mean ± SEM.
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Figure 3. Virus-specific CD8+ T cells expand in RRV-LCMV-infected mice
Three-to-four week-old C57BL/6J mice were mock-inoculated (n = 3) or inoculated with 
103 PFU of WT RRV (n = 4) or RRV-LCMV (5 dpi, n = 6; 7 dpi n = 9; 10 dpi, n = 9; 14 
dpi, n = 6). At the indicated day post-inoculation, leukocytes were isolated from spleens, 
draining popliteal lymph nodes (pLN), and quadriceps muscles (following enzymatic 
digestion) for FACS analysis. Spleen cells from a mouse inoculated with LCMV-Armstrong 
i.p. and harvested on day 7 pi was used as a control for gp33 tetramer staining. (A) 
Representative flow plots from 10 dpi indicating the gating strategy to identify 
CD8+CD4−gp33+ T cells, after gating on lymphocytes and excluding doublets. (B) 
Frequency (top panel) and total number (bottom panel) of CD8+CD4− T cells and 
CD8+CD4−gp33+ T cells in the spleen, pLN, and muscle tissues. Data are combined from 2–
3 independent experiments. Graphs represent the arithmetic mean ± SEM. ** P < 0.01, as 
determined by two-way, unpaired t-tests.
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Figure 4. Virus-specific CD8+ T cells from the spleen and muscle tissues of RRV-LCMV-infected 
mice express different levels of activation markers and produce cytokines following ex vivo 
restimulation
(A and B) Three-to-four week-old C57BL/6J mice were mock-inoculated (n = 3) or 
inoculated with 103 PFU of RRV-LCMV (n = 9). At 10 dpi, leukocytes were isolated from 
spleens and quadriceps muscles (following enzymatic digestion) for FACS analysis. Spleen 
cells from a mock-inoculated mouse and a mouse inoculated with LCMV-Armstrong i.p. 
and harvested on day 7 pi was used as a control for gp33 tetramer staining. (A) 
Representative histogram plots showing CD44 and CD62L staining on T cells. (B) 
Frequency of activation marker-positive T cells in spleen compared to muscle tissue from 
RRV-LCMV-inoculated mice. Data are combined from two independent experiments. 
Graphs represent the arithmetic mean ± SEM. * P > 0.05, ** P < 0.01, as determined by 
two-tailed, unpaired t-test with or without Welch's correction. (C and D) Three-to-four 
week-old C57BL/6J mice were or inoculated with 103 PFU of WT RRV (n = 4) or RRV-
LCMV (n = 9). At 10 dpi, leukocytes were isolated from spleens and quadriceps muscles 
(following enzymatic digestion) for FACS analysis. (C) Representative histogram plots 
showing CD44 and CD62L staining on total CD8+ T cells from WT RRV- or RRV-LCMV-
inoculated mice compared to unstained splenocytes. (D) Frequency of activation marker-
positive T cells from the spleen or muscle tissue of WT RRV- or RRV-LCMV-inoculated 
mice. Data are combined from two independent experiments. Graphs represent the 
arithmetic mean ± SEM. ** P = 0.002, as determined by a two-way, unpaired t-test. (E–G) 
Three-to-four week-old C57BL/6J mice were inoculated with 103 PFU of WT RRV (n = 2) 
or RRV-LCMV (n = 5). At 10 dpi, infiltrating leukocytes were isolated from the quadriceps 
muscles (following enzymatic digestion) and restimulated ex vivo for 5 hours with gp33 
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peptide followed by intracellular cytokine staining. Spleen cells from a mouse inoculated 
with LCMV-Arm i.p. and harvested on day 7 pi was used as a control for gp33 peptide 
restimulation. (E) Representative flow plots showing IFN-γ, TNF-α, and IL-2 production by 
CD8+CD4− T cells following stimulation with antigen presenting cells (APCs) alone (top 
panel) or APCs with peptide (middle and bottom panels). (F) Graph showing the distribution 
of zero, one, two, or three-cytokine-producing CD8+CD4− T cells isolated from quadriceps 
muscle tissue of RRV-LCMV-inoculated mice at 10 dpi. (G) Total number of one, two, or 
three-cytokine-producing CD8+CD4− T cells. Graphs represent the arithmetic mean ± SEM.
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Figure 5. CD8α−/− mice have increased RRV loads in muscle but not joint tissue at 14 and 21 dpi
Three-to-four week-old C57BL/6J WT (7 dpi, n = 7; 14 dpi, n = 10; 21 dpi, n = 5) and 
CD8α−/− (7 dpi, n = 12; 14 dpi, n = 7; 21 dpi, n = 5) mice were inoculated with 103 PFU of 
RRV. At 7, 14, and 21 dpi mice were sacrificed, perfused by intracardial injection with 1× 
PBS, and total RNA was isolated from the (A) right quadriceps muscle and (B) right ankle/
foot. RRV genome levels were quantified by absolute RT-qPCR. Horizontal bars indicate 
the mean. * P < 0.05, ** P < 0.01, *** P < 0.001, as determined by one-way ANOVA 
followed by Tukey's multiple comparison test. (C and D) Three-to-four week-old C57BL/6J 
WT (n = 21) and CD8α−/− (n = 28) mice were inoculated with 103 PFU of RRV and 
assessed for (C) weight gain and (D) musculoskeletal disease signs including loss of 
gripping ability and altered gait at 24-hour intervals. Each data point represents the 
arithmetic mean ± SD.
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Figure 6. CD8 T cell depletion significantly increases RRV loads in muscle but not joint tissue at 
14
Three-to-four week-old C57BL/6J WT mice were inoculated with 103 PFU of RRV and 
treated with an anti-CD8α antibody (n = 4) or a control antibody (n = 4) on days 7 and 12 pi. 
At 14 dpi mice were sacrificed and perfused by intracardial injection with 1× PBS. Spleens 
were harvested for FACS analysis; the right quadriceps and right ankle/foot were dissected 
for RNA analysis. Spleen cells were stained for CD3, CD4, and CD8β to confirm efficient 
depletion. (A) Representative flow plots demonstrating depletion of CD8α+ T cells. (B) 
Frequency of CD3+CD8β+ T cells in spleens. Total RNA was isolated from the (C) right 
quadriceps muscle and (D) right ankle/foot, and RRV genome levels were quantified by 
absolute RT-qPCR. Horizontal bars indicate the mean. P-value was determined by a two-
tailed, unpaired t-test. Data are combined from two independent experiments.
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Figure 7. T cells contribute to the control of RRV infection in the absence of B cells and Ab
Pan T cells were negatively selected from the spleen of WT mice, and 2.5 × 106 cells were 
injected i.p. into Rag1−/− mice (n = 8) one day prior to RRV inoculation. Alternatively, 
CD8+ T cells were negatively selected from the spleen of WT mice, and 1 × 106 cells were 
injected i.p. into Rag1−/− mice (n = 4) one day prior to RRV inoculation. As a negative 
control, 6 Rag1−/− mice received media alone on day −1. Spleens and left quadriceps were 
harvested at 14 dpi for flow cytometric analysis of the presence of T cells, as shown in (A). 
Cells were gated on Gr-1−B220−, then CD3+, then divided into CD4+ or CD8+. The percent 
of CD3+CD8+ T cells (squares) and CD3+CD4+ T cells (circles) in the spleen (closed 
shapes) and muscle (open shapes) are graphed in (B), and the total number of CD3+CD8+ T 
cells and CD3+CD4+ T cells in the spleen and muscle are graphed in (C). Right quadriceps 
(D) and right ankle/foot (not shown) were harvested for analysis of RRV RNA. Horizontal 
bar indicates the mean. ** P < 0.01, *** P < 0.001, as determined by one-way ANOVA 
followed by Tukey's multiple comparison test. (E) Serum viremia levels measured by direct 
plaque assay on BHK-21 cells. Dashed line indicates the limit of detection. (F) The percent 
of CD3+ T cells (gated on Gr-1−B220− cells) in the spleen plotted against the corresponding 
RRV RNA level in the quadriceps muscle at 14 dpi. Linear regression analysis was 
performed to determine the r2 values and P-values. Data are combined from four 
independent experiments.
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